KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) EPS (Basic) (2016 - 2025)

Resmed's EPS (Basic) history spans 17 years, with the latest figure at $2.69 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 14.47% year-over-year to $2.69; the TTM value through Dec 2025 reached $10.15, up 19.55%, while the annual FY2025 figure was $9.55, 37.61% up from the prior year.
  • EPS (Basic) reached $2.69 in Q4 2025 per RMD's latest filing, up from $2.38 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.69 in Q4 2025 to a low of -$0.54 in Q1 2021.
  • Average EPS (Basic) over 5 years is $1.69, with a median of $1.55 recorded in 2023.
  • Peak YoY movement for EPS (Basic): plummeted 147.79% in 2021, then skyrocketed 325.93% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $1.38 in 2021, then rose by 10.87% to $1.53 in 2022, then fell by 7.19% to $1.42 in 2023, then skyrocketed by 65.49% to $2.35 in 2024, then increased by 14.47% to $2.69 in 2025.
  • Per Business Quant, the three most recent readings for RMD's EPS (Basic) are $2.69 (Q4 2025), $2.38 (Q3 2025), and $2.59 (Q2 2025).